NEVVI Medicare utilization intelligence
or

← back

Provider profile

SMITH, RAYMOND MD

Medical Oncology · NPI 1477526259 · QUINCY, IL

3
Groups
44
Codes · 2024
77,750
Disclosed services

SMITH, RAYMOND is a Medical Oncology in QUINCY, IL, a member of 3 medical groups, who billed 44 distinct codes to Medicare Part B in 2024.

Groups: QUINCY PHYSICIANS AND SURGEONS CLINIC, PLLC (QUINCY, IL) · SCOTLAND COUNTY MEMORIAL HOSPITAL (MEMPHIS, MO) · SOUTHEAST IOWA REGIONAL MEDICAL CENTER INC (WEST BURLINGTON, IA) — member of 3 groups; the volumes below are this clinician's personal volume and are not attributed to any single group

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

77,750
disclosed services
44
codes billed to Medicare Part B
Prior year · CY2023 109,231 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1439 Injection, ferric carboxymaltose, 1 mg
J9271 Injection, pembrolizumab, 1 mg
J0897 Injection, denosumab, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J1453 Injection, fosaprepitant, 1 mg
J1561 Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J1626 Injection, granisetron hydrochloride, 100 mcg
J2919 Injection, methylprednisolone sodium succinate, 5 mg
J2469 Injection, palonosetron hcl, 25 mcg
J9181 Injection, etoposide, 10 mg
Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96413 Administration of chemotherapy into vein, 1 hour or less
96375 Injection of additional new drug or substance into vein
J3480 Injection, potassium chloride, per 2 meq
J3475 Injection, magnesium sulfate, per 500 mg
96372 Injection of drug or substance under skin or into muscle
96415 Administration of chemotherapy into vein, each additional hour
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J9045 Injection, carboplatin, 50 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96417 Administration of additional new drug or substance into vein, 1 hour or less
77014 Ct guidance for insertion of radiation therapy fields
36591 Collection of blood sample from implanted device
J7030 Infusion, normal saline solution , 1000 cc
G6015 Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session
J3489 Injection, zoledronic acid, 1 mg
96360 Infusion into a vein for hydration, 31-60 minutes
96523 Irrigation of implanted venous access drug delivery device
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
J3490 Unclassified drugs
96377 Application of on-body injector for under skin injection
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes
77427 Radiation treatment management, 5 treatment sessions
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.